Lippo Karawaci Tbk (LPKR) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Lippo Karawaci Tbk stock IDR 114, price IDR 40, upside +184.6%, quality 27 out of 100. Rating: strongly undervalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range 38.00 IDR – 197.00 IDR · fair‑value band 83.76 IDR – 169.40 IDR · the 40.00 IDR price screens below the 113.84 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.
Follow Lippo Karawaci Tbk in your weekly email
Every Wednesday you see whether Lippo Karawaci Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Lippo Karawaci Tbk engages in real estate development, healthcare and lifestyle businesses in Indonesia.
Show moreShow less
The company is also involved in investment, development, trading, home care, and financing activities; installation and water treatment; town management; urban development; marketing and building management; clean water and waste management; hotel management; catering service; and provision of accommodation and burial services.
PT Lippo Karawaci Tbk founded in 1990 and is based in Tangerang, Indonesia.
Stock analysis
Lippo Karawaci Tbk (LPKR) currently trades at 40.00 IDR, while our model-based Fair Value estimate is 113.84 IDR, implying the stock looks roughly 65% undervalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 146.16 IDR per share, and 11 of the 15 models we run sit above the 40.00 IDR price.
Bear case: the Earnings-Based group reads lowest at 55.93 IDR, and 4 of the 15 models stay below the price. Data coverage for this calculation is low.
Scenario range: 83.76 IDR (bear) to 169.40 IDR (bull), the price of 40.00 IDR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
Lippo Karawaci Tbk reported revenue of 8.8T IDR in FY2025 versus 16.1T IDR in FY2021, a compound −14.0%/yr. Reported net income was 470B IDR in FY2025.
Key figures
Market cap 2.8T IDR (≈ $157M) Micro · P/E ratio 4.0 · P/S ratio 0.34 · EPS (TTM) 10.11 IDR · Net margin 8.6% · Return on equity 2.6% · Return on assets (EBIT) 9.5% (5-year average) · Operating margin 15.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).
What moves the price
The share trades about 69% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 185%, LPKR screens cheaper than that median.
Fair Value models
Bear83.76 IDRFair Value 113.84 IDRBull169.40 IDR
Price 40.00 IDR · Upside +184.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (8.67 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
What shareholders gained per year (last 3 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+82.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+82.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1% → 7%
⚠ Revenue per share shrinking 2.0%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 233 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score27 · Bottom 25%
Fair Value upside+184.6% · Top 25%
Profitability
Return on equity (12 months)2.6% · Below median
Return on assets1.0% · Below median
Net margin (12 months)8.6% · Above median
Operating margin (12 months)15.5% · Above median
Growth and dividend
Revenue growth (quarter YoY)−12.1% · Bottom 25%
Balance sheet
Debt / equity0.13× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Lippo Karawaci Tbk (LPKR) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 113.84 IDR versus a price of 40.00 IDR, about +185% upside (undervalued).
What is the fair value of LPKR?
Our model-based fair value for Lippo Karawaci Tbk is 113.84 IDR (as of Nov 6, 2026), built from audited fundamentals. The current price: 40.00 IDR.
What is the quality score of LPKR?
Lippo Karawaci Tbk has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lippo Karawaci Tbk (LPKR)?
Our model-based price target is the fair value of 113.84 IDR (as of Nov 6, 2026) from 15 valuation models. Cautious scenario 83.76 IDR, optimistic scenario 169.40 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Lippo Karawaci Tbk stock forecast for 2026?
Our models put fair value at 113.84 IDR, about +185% upside versus a price of 40.00 IDR (undervalued). Cautious scenario 83.76 IDR, optimistic scenario 169.40 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Lippo Karawaci Tbk (LPKR)?
Lippo Karawaci Tbk reported trailing-twelve-month revenue of about 8.3T IDR (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Lippo Karawaci Tbk (LPKR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lippo Karawaci Tbk it is 113.84 IDR per share (as of Nov 6, 2026), against a price of 40.00 IDR. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Lippo Karawaci Tbk stock overvalued or undervalued in 2026?
As of Nov 6, 2026, LPKR trades below its calculated fair value: price 40.00 IDR, fair value 113.84 IDR, a gap of about +185% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LPKR?
No. The price is what the market pays today (40.00 IDR); the fair value is what the company's own numbers justify (113.84 IDR). For Lippo Karawaci Tbk the two are 73.84 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Lippo Karawaci Tbk worth?
The market values Lippo Karawaci Tbk at about 2.8T IDR (market capitalisation, as of Nov 6, 2026). Per share that is 40.00 IDR; our models calculate a fair value of 113.84 IDR per share.
What do the bullish and bearish scenarios say about LPKR?
Our models span a range for Lippo Karawaci Tbk: cautious scenario 83.76 IDR, base 113.84 IDR, optimistic 169.40 IDR per share (as of Nov 6, 2026, price 40.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LPKR?
Lippo Karawaci Tbk trades at a price-to-earnings ratio of 4.0 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 113.84 IDR is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 15.4. Other multiples: PEG 1.6, P/B 0.1, P/S 0.3, EV/EBITDA 5.1.
What is the PEG ratio of LPKR?
The PEG ratio of Lippo Karawaci Tbk is 1.65 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Lippo Karawaci Tbk (LPKR)?
Balance-sheet figures for Lippo Karawaci Tbk (as of Nov 6, 2026): return on equity 2.6%, debt of 0.13 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is LPKR from its 52-week high?
Lippo Karawaci Tbk trades at 40.00 IDR, about 69% below its 52-week high of 128.00 IDR and 5% above the low of 38.00 IDR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 113.84 IDR is for.
Which stocks are comparable to Lippo Karawaci Tbk?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lippo Karawaci Tbk stock attractive at the current price?
The data as of Nov 6, 2026: price 40.00 IDR, calculated fair value 113.84 IDR (+185%), Quality Score 27/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LPKR calculated?
We run Lippo Karawaci Tbk through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 113.84 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Lippo Karawaci Tbk currently trades 65% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lippo Karawaci Tbk (LPKR)?
The closing price on Nov 6, 2026 was 40.00 IDR. Our model-based fair value is 113.84 IDR, about +185% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lippo Karawaci Tbk right now?
The large discount to fair value meets weak quality (27/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (83.76 IDR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (83.76 IDR to 169.40 IDR) leaves room in how you read the outcome.
Where does the earnings growth of Lippo Karawaci Tbk (LPKR) come from?
Earnings per share at Lippo Karawaci Tbk grew +11.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share −4.8 %, EBIT margin +12.4 %, tax rate +2.3 %, residual (interest, one-offs) +1.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Lippo Karawaci Tbk
How large is the market capitalisation of Lippo Karawaci Tbk (LPKR)?
The market capitalisation of Lippo Karawaci Tbk is 2.8T IDR (≈ $157M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lippo Karawaci Tbk (LPKR)?
The price-to-sales ratio of Lippo Karawaci Tbk is 0.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lippo Karawaci Tbk (LPKR)?
Earnings per share at Lippo Karawaci Tbk are 10.11 IDR (price ÷ EPS = P/E 4.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Lippo Karawaci Tbk (LPKR)?
The net margin of Lippo Karawaci Tbk is 8.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lippo Karawaci Tbk (LPKR)?
The return on equity (ROE) of Lippo Karawaci Tbk is 2.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lippo Karawaci Tbk (LPKR)?
On an EBIT basis the return on assets of Lippo Karawaci Tbk is 9.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lippo Karawaci Tbk (LPKR)?
The operating margin of Lippo Karawaci Tbk is 15.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lippo Karawaci Tbk (LPKR)?
Revenue at Lippo Karawaci Tbk is growing −12.1% versus a year earlier (3y avg −15.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lippo Karawaci Tbk (LPKR)?
Earnings per share at Lippo Karawaci Tbk are growing −36.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Lippo Karawaci Tbk (LPKR) generate?
The free cash flow of Lippo Karawaci Tbk is −1.8T IDR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Lippo Karawaci Tbk (LPKR) carry?
The net debt of Lippo Karawaci Tbk is 7.7T IDR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Lippo Karawaci Tbk in the live analysis
One click puts Lippo Karawaci Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026